Strategic Acquisition Experimur is part of the Frontage family after a 2022 acquisition, signaling strong backing and extended resources to support complex toxicology programs and GLP-compliant studies.

Toxicology Expertise A long-tenured, highly skilled team with experience across multiple animal models and full-spectrum toxicology testing positions Experimur as a reliable partner for preclinical safety programs and specialized studies.

Facility Advantage Owns a 54,000 square foot AAALAC-accredited, USDA-registered facility with in-house histology, pathology, clinical pathology, and analytical chemistry, enabling integrated, faster study execution.

Collaborative Opportunities Past collaboration with Silo Pharma and ongoing access to Frontage Labs’ network suggests potential for joint programs, broader client introductions, and expanded service offerings.

Mid-market Focus Revenue in the 10–25 million range and a mid-sized team indicate a nimble partner with high service quality and potential for scaled toxicology programs for mid-market biotech and pharma customers.